Kugelberg-Welander Syndrome (Spinal Muscular Atrophy Type III)
Related Subjects:
|Kugelberg-Welander Syndrome (Spinal Muscular Atrophy Type III)
|Werdnig–Hoffman Disease (Spinal Muscular Atrophy Type 1)
|Spinal Muscular Atrophy (SMA)
|Poliomyelitis
|Post Polio Syndrome
|Anterior Horn Cell diseases
|Transverse myelitis
|Acute Disseminated Encephalomyelitis
|Cervical spondylosis
|Spinal Cord Anatomy
|Acute Disc Prolapse
|Spinal Cord Compression
|Spinal Cord Haematoma
|Foix-Alajouanine syndrome
|Cauda Equina
|Conus Medullaris syndrome
|Anterior Spinal Cord syndrome
|Central Spinal Cord syndrome
|Brown-Sequard Spinal Cord syndrome
🧬 About
- Kugelberg–Welander Syndrome = Spinal Muscular Atrophy (SMA) Type III, a childhood-onset motor neuron disease causing progressive weakness and muscle wasting.
- Caused by mutations in the SMN1 gene on Chromosome 5q13.
- Onset usually after age 2, slower progression than SMA I/II, and many patients survive into adulthood.
⚙️ Aetiology & Pathophysiology
- Inheritance: Autosomal recessive (both SMN1 alleles affected).
- Mechanism: Deficiency of survival motor neuron (SMN) protein → degeneration of anterior horn cells → lower motor neuron weakness.
- Target: Voluntary muscles, particularly proximal groups (hip and shoulder girdle).
🩺 Clinical Features
- Onset: Typically between 2–10 years.
- 👟 Walking difficulties: Frequent falls, difficulty running or climbing stairs.
- 💪 Proximal muscle weakness: Wasting of thighs/shoulders; pseudohypertrophy of calves may occur.
- 🦵 Reflexes: Absent/reduced knee jerks.
- ⚡ Fasciculations: Visible twitching in muscles (esp. tongue, limb muscles).
- 🧑🦯 Many lose ambulation in adolescence or early adulthood, though some remain ambulant long-term.
- Rare: ophthalmoplegia or swallowing problems (much less common than SMA I).
🧪 Investigations
- CK: May be mildly elevated.
- EMG: Shows denervation (fibrillations, positive sharp waves).
- Genetic testing: Confirms SMN1 mutation/deletion (diagnostic gold standard).
- Muscle biopsy: Rarely needed now; would show grouped atrophy.
💊 Management
- Supportive: Physiotherapy, orthotics, occupational therapy, exercise programmes to maintain mobility.
- Respiratory monitoring: Less severe than SMA I/II but still important in advanced disease.
- Nutritional support: Prevents undernutrition and supports muscle function.
- Disease-modifying therapies:
- Nusinersen (Spinraza): Increases SMN protein production.
- Risdiplam (Evrysdi): Oral splicing modifier.
- Onasemnogene abeparvovec (Zolgensma): Gene therapy (mainly in younger children).
📉 Prognosis
- Variable - many retain ambulation into adulthood, some lose it in adolescence.
- Respiratory failure less common than SMA I/II but may occur late.
- With new therapies, outcomes and quality of life are improving significantly.
🧾 Differential Diagnosis
- Duchenne/Becker muscular dystrophy (proximal weakness, raised CK, X-linked).
- Charcot–Marie–Tooth disease (distal weakness, foot deformities, sensory involvement).
- Congenital myopathies.
